A Phase 1b Dose-Finding Study of ARO-HIF2 in Patients with Advanced Clear Cell Renal Cell Carcinoma

Brief description of study

The purpose of the study is to assess the safety and tolerability of ARO-HIF2, administered by IV infusion. We want to know the best dose treatment for patients with advanced clear cell renal cell carcinoma (ccRCC). The study drug ARO-HIF2 is investigational, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.


Clinical Study Identifier: s19-01447
ClinicalTrials.gov Identifier: NCT04169711


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.